The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Michael Gordon Leahy
No relevant relationships to disclose
Binh Bui Nguyen
Consultant or Advisory Role - Novartis; PharmaMar
Shreyaskumar Patel
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Peter Hohenberger
No relevant relationships to disclose
George D. Demetri
No relevant relationships to disclose
Pilar Lardelli
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Iratxe Perez
Employment or Leadership Position - PharmaMar
Stock Ownership - PharmaMar
Sant P. Chawla
No relevant relationships to disclose